NCT02959905View on ClinicalTrials.gov

Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

December 22, 2016

Primary Completion Date

September 1, 2020

Study Completion Date

May 20, 2022

Conditions
Solid Cancer
Interventions
BIOLOGICAL

TSA-CTL

Patients will receive TSA-CTL iv over 20-30 minutes on day 0.

DRUG

Cyclophosphamide

Cyclophosphamide 500 mg/m2/day iv on day -5 for one day.

DRUG

Fludarabine

Fludarabine 25 mg/m2/day iv over 30 minutes on day -5 and -4 for two days.

DRUG

Cyclophosphamide

Cyclophosphamide 500 mg/m2/day iv on day -5 and -4 for two days.

Trial Locations (1)

510030

Sun Yat-Sen University Cancer Center, Guangzhou

All Listed Sponsors
collaborator

Sun Yat-sen University

OTHER

lead

BGI, China

OTHER

NCT02959905 - Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes) | Biotech Hunter | Biotech Hunter